228.74
-0.16(-0.07%)
Currency In USD
Address
21823 30th Drive SE
Bothell, WA 98021
United States of America
Phone
425 527 4000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3256
First IPO Date
March 09, 2001
| Name | Title | Pay | Year Born |
| Mr. David R. Epstein B.Sc., M.B.A. | Chief Executive Officer & Director | 1.39M | 1962 |
| Dr. Vaughn B. Himes Ph.D. | Chief Technical Officer | 1.08M | 1961 |
| Mr. Charles R. Romp | Executive Vice President of Commercial U.S. | 1.08M | 1968 |
| Mr. Todd E. Simpson | Chief Financial Officer | 1.26M | 1961 |
| Peggy Pinkston | Senior Vice President of Investor Relations | 0 | N/A |
| Mr. Christopher P. Pawlowicz | Executive Vice President of HR | 0 | N/A |
| Mr. William Compton | Senior Vice President of Global Information Technology & Chief Information Officer | 0 | N/A |
| Ms. Peggy Pinkston | Chief HR Officer | 0 | N/A |
| Mr. Matt Skelton | Vice President of Marketing | 0 | N/A |
| Mr. David Caouette | Vice President of Corporate Communications | 0 | N/A |
| Ms. Peggy M. Pinkston | Chief Human Resources Officer | 0 | N/A |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.